Schlapbach, Christoph; Yerly, Daniel; Daubner, Barbara; Yawalkar, Nikhil; Hunger, Robert E (2011). Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. Journal of dermatological science, 62(2), pp. 75-83. Amsterdam: Elsevier 10.1016/j.jdermsci.2011.02.001
Full text not available from this repository. (Request a copy)There is currently no curative therapy for cutaneous T cell lymphoma (CTCL). New therapies are therefore needed. Telomerase, the enzyme that allows for unrestricted cell divisions of cancer cells, is a promising target for cancer therapy. The telomerase-specific peptide vaccination GV1001 has shown promising results in previous studies. Since telomerase is expressed in malignant cells of CTCL, GV1001 vaccination in CTCL is a promising new therapeutic approach.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology 04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology |
UniBE Contributor: |
Schlapbach, Christoph, Yerly, Daniel, Yawalkar, Nikhil, Hunger, Robert |
ISSN: |
0923-1811 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:21 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1016/j.jdermsci.2011.02.001 |
PubMed ID: |
21377838 |
Web of Science ID: |
000290645300001 |
URI: |
https://boris.unibe.ch/id/eprint/7072 (FactScience: 212222) |
Actions (login required)
 |
Edit item |